Plain-English translation of NCT05389319 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new COVID-19 booster vaccine called in healthy adults. Researchers want to find the safest and most effective dose of this medication by testing different amounts with different groups of participants. The vaccine is designed to boost immunity in people who have already been vaccinated against COVID-19.
Scientists are developing new booster vaccines to help protect people from COVID-19 variants and keep immunity strong over time. This trial will help determine whether this new medication is safe and whether it can trigger a strong immune response in people who have already been vaccinated.
You will receive one injection of the study vaccine on Day 1, then return for check-up visits at Days 4, 8, 15, 29, and at 3 and 6 months after vaccination. You'll also receive brief phone calls on Days 2 and 3 to check how you're feeling. At these visits, researchers will draw blood, ask about any side effects, and run tests to measure how well your immune system responds to the vaccine. The entire study lasts about six months.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
Germany
Phase
Safety & dosing
Sponsor
University Hospital Tuebingen
Collaborators
FGK Clinical Research GmbH, VisMederi srl
Enrollment target
~96 participants
Started
June 2022
Primary completion
December 2026
Age range
18 Years – 55 Years
Last updated on clinicaltrials.gov in June 2026.